PURE Bioscience, Inc. (NASDAQ: PURE ), creator of the patented silver dihydrogen citrate (SDC) antimicrobial and SDC-based products, today announced that it will hold its 2012 annual meeting of stockholders on July 25, 2012. The location, time and other details of the 2012 annual meeting will be announced in PURE’s proxy materials, which will be sent to its stockholders prior to the 2012 annual meeting. Because the 2012 annual meeting date is more than 30 days from the one year anniversary of PURE’s prior annual meeting, PURE has set a new deadline for its receipt of stockholder proposals submitted pursuant to Rule 14a-8 promulgated under the Securities Exchange Act of 1934, as amended, for inclusion in PURE’s proxy materials for the 2012 annual meeting. To be considered timely, such proposals must be received by PURE’s Secretary at PURE’s principal executive offices no later than the close of business on April 26, 2012. In addition, pursuant to PURE’s bylaws, stockholders who wish to present a proposal at the 2012 annual meeting that is not intended for inclusion in PURE’s proxy materials must provide written notice of the proposal that is received by PURE’s Secretary at PURE’s principal executive offices no later than the close of business on April 26, 2012. All such proposals and notices must comply in all respects with applicable rules of the Securities and Exchange Commission and the requirements set forth in PURE’s bylaws. About PURE Bioscience, Inc. PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com. This press release includes statements that may constitute “forward-looking” statements, sometimes containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, without limitation, Pure’s cash position and liquidity requirements, the prevailing market price of Pure’s common stock, acceptance of the Pure's current and future products and services in the marketplace, the ability of Pure to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in Pure's filings with the Securities and Exchange Commission. By making these forward-looking statements, Pure undertakes no obligation to update these statements for revisions or changes after the date of this release.